1Lacey DL,Tan HL,Lu J,et al.Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo[J]. Am J Pathol,2000,157(2):435～448.
2Theill LE,Boyle WJ,Penninger JM.RANK-L and RANK:T cells,bone loss,and mammalian evolution[J]. Annu Rev Immunol,2002,20:795～823.
3Shiotani A,Takami M,Itoh K,et al.Regulation of osteoclast differentiation and function by receptor activator of NF-kB ligand and osteoprotegerin[J]. Anat Rec,2002,268(2):137～146.
4Bell NH.RANK ligand and the regulation of skeletal remodeling[J]. J Clin Invest,2003,111(8):1120～1122.
5Inoue D,Matsumoto T.Recent advances in basic research of bone metabolism[J]. Nippon Rinsho,2002,60 Suppl 3:25～33.
6Jones DH,Kong YY,Penningger JM.Role of RANKL and RANK in bone loss and arthritis[J]. Ann Rheum Dis,2002,61 Suppl 2:32～39.
7Katagiri T,Takahashi N.Regulatory mechanisms of osteoblast and osteoclast differentiation[J]. Oral Dis,2002,8(3):147～159.
8Kim N,Takami M,Rho J,et al.A novel member of the leukocyte receptor complex regulates osteoclast differentiation[J]. J Exp Med,2002,195(2):201～209.
9Nagai M,Kyakumato S,Sato N.Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation[J]. Biochem Biophys Res Commun,2000,269(2):532～536.
10Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation[J]. Nature, 2003,423(6937):337～342.
9Utting JC,Robins SP,Brandao-Burch A,et al.Hypoxia inhibits the growth,differentiation and bone-forming capacity of rat osteoblasts.Exprimental.Cell Reseach.2006;312(10)1693-1702.
10Consensus Development Conference:Prophylaxis and Treatment of osteoporosis.Am J Med.1991;90:107-110.
